Alphageneron Pharmaceuticals Inc., of Cambridge, Mass., said it signed an exclusive license agreement with Multimmune GmbH, of Munich, Germany, for its clinical-stage autologous NK cell therapy and companion diagnostic platform for all fields worldwide. The autologous NK cell therapy redirects NK cells to target a cell membrane form of heat-shock protein 70, which has been discovered to be highly expressed on many cancer cells but not on healthy cells, according to Alphageneron. The company will pay Multimmune an unnamed amount in developmental and regulatory milestones, plus post-commercialization royalties. In July, the two companies signed a collaboration agreement to repurpose the NK cell therapy platform for treating SARS-COV-2.
Curevac NV, of Tübingen, Germany, and Boston, said it will collaborate with the U.K. government to develop and manufacture vaccine candidates against SARS-CoV-2 variants. Any vaccine candidates will be manufactured and distributed in the U.K. and its overseas and dependent territories. Clinical studies will be expedited in the U.K. to secure emergency or conditional marketing authorizations for selected vaccine candidates against the most threatening variant viruses, according to Curevac.
GHP Noetic Science-Psychedelic Pharma Inc., of Toronto, a capital pool company, said it will acquire all issued and outstanding securities of Diamond Therapeutics Inc., also of Toronto, in exchange for GHP’s securities. The transaction will result in a reverse takeover of GHP by Diamond, which is developing therapeutics from psychedelic compounds for treating mental health disorders.
Hyloris Pharmaceuticals SA, Liege, Belgium, and Purna Female Healthcare (PFH), a spin-off founded by Purna Pharmaceuticals NV and Creafund NV, agreed to develop and commercialize a combination therapy for treating severe and recurrent vulvovaginal candidiasis, a vaginal fungal infection commonly caused by the yeast Candida albicans. PFH is a special purpose vehicle founded to exclusively develop a local topical combination formulation of the antifungal miconazole with domiphen bromide (MCZ-DB). Hyloris committed to milestone-related investments of up to €4.3 million (US$5.18) and will lead the commercialization and out-licensing activities. Hyloris owns 20% of PFH and could receive up to 45% of net profits generated by PFH.
Onxeo SA, of Paris, said it entered a clinical research agreement with Institut Curie, a French cancer center, to conduct a phase Ib/II study to evaluate AsiDNA, Onxeo’s DNA damage response inhibitor, in combination with radiotherapy in children with high-grade glioma relapse and eligible for re-irradiation. AsiDNA is based on a decoy and agonist mechanism acting upstream of multiple DNA damage response pathways.
Pfizer Inc., of New York, said the U.S. Patent and Trademark Office issued a Patent Term Extension (PTE) certificate for Ibrance (palbociclib), extending the term of U.S. Patent No. RE47,739 (‘739) until March 5, 2027. The certificate was granted under the patent restoration provisions of the Drug Price Competition and Patent Term Restoration Act of 1984. The PTE will be listed in the Orange Book published by the FDA. The extension does not include potential pediatric exclusivity. Ibrance is an oral inhibitor of CDKs 4 and 6, key regulators of the cell cycle that trigger cellular progression. In the U.S., it is indicated for treating adults with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men or with fulvestrant in patients with disease progression following endocrine therapy.